Yavuz Tekelioğlu1, Hikmet Uzun. 1. Division of Histology and Embryology, Karadeniz Technical University, Medical Faculty, Trabzon, Turkey. ytekeli61@yahoo.com
Abstract
BACKGROUND: Inflammatory bowel diseases (IBDs), Crohn's disease, and ulcerative colitis are considered to be chronic inflammatory disorders implicated with recurrent tissue damage to the intestine. There is a positive correlation between platelet-leukocyte aggregates and ischemic vascular risk. There are limited data about the relationship between platelet-leukocyte aggregates and IBD. This study was designed to determine whether platelet-leukocyte aggregates increase in IBD, and whether a relationship exists between the elevation of platelet-leukocyte aggregates and disease activity. METHODS: A total of 20 patients with IBD (16 with ulcerative colitis and 4 with Crohn's disease) and 20 healthy controls participated in our study. Nine patients were in active-phase IBD, whereas 11 patients were in inactive phase. To show the presence of thrombocyte aggregates, the monoclonal antibodies such as Isotype IgG1 mouse antihuman CD42b-PE (phycoerythrin) (Beckman Coulter IMI417), Isotype IgG1 mouse antihuman CD45-FITC (fluorescein isothiocyanate) (Beckman Coulter IM0782), and Isotype IgG2a mouse antihuman CD45RO-FITC (Beckman Coulter IMI247) were used. Additionally, the values of platelet-neutrophil aggregates were measured in peripheral blood samples using flow cytometry techniques. RESULTS: The levels of platelet-leukocyte aggregates in blood samples were found to be significantly higher during both the active and inactive phases in patients with IBD. There were no statistically significant differences between active-phase and inactive-phase patients. CONCLUSION: We determined that the patient group had significantly higher platelet-leukocyte aggregate levels compared with the control group. This finding suggests that platelet-leukocyte aggregates may play a role in the development of IBD.
BACKGROUND:Inflammatory bowel diseases (IBDs), Crohn's disease, and ulcerative colitis are considered to be chronic inflammatory disorders implicated with recurrent tissue damage to the intestine. There is a positive correlation between platelet-leukocyte aggregates and ischemic vascular risk. There are limited data about the relationship between platelet-leukocyte aggregates and IBD. This study was designed to determine whether platelet-leukocyte aggregates increase in IBD, and whether a relationship exists between the elevation of platelet-leukocyte aggregates and disease activity. METHODS: A total of 20 patients with IBD (16 with ulcerative colitis and 4 with Crohn's disease) and 20 healthy controls participated in our study. Nine patients were in active-phase IBD, whereas 11 patients were in inactive phase. To show the presence of thrombocyte aggregates, the monoclonal antibodies such as Isotype IgG1 mouse antihuman CD42b-PE (phycoerythrin) (Beckman Coulter IMI417), Isotype IgG1 mouse antihuman CD45-FITC (fluorescein isothiocyanate) (Beckman Coulter IM0782), and Isotype IgG2a mouse antihuman CD45RO-FITC (Beckman Coulter IMI247) were used. Additionally, the values of platelet-neutrophil aggregates were measured in peripheral blood samples using flow cytometry techniques. RESULTS: The levels of platelet-leukocyte aggregates in blood samples were found to be significantly higher during both the active and inactive phases in patients with IBD. There were no statistically significant differences between active-phase and inactive-phase patients. CONCLUSION: We determined that the patient group had significantly higher platelet-leukocyte aggregate levels compared with the control group. This finding suggests that platelet-leukocyte aggregates may play a role in the development of IBD.
Authors: Adam Z Blatt; Gurpanna Saggu; Koustubh V Kulkarni; Claudio Cortes; Joshua M Thurman; Daniel Ricklin; John D Lambris; Jesus G Valenzuela; Viviana P Ferreira Journal: J Immunol Date: 2016-04-25 Impact factor: 5.422
Authors: G Ed Rainger; Myriam Chimen; Matthew J Harrison; Clara M Yates; Paul Harrison; Stephen P Watson; Marie Lordkipanidzé; Gerard B Nash Journal: Platelets Date: 2015-07-21 Impact factor: 3.862
Authors: Myriam Chimen; Aigli Evryviadou; Clare L Box; Matthew J Harrison; Jon Hazeldine; Lea H Dib; Sahithi J Kuravi; Holly Payne; Joshua M J Price; Dean Kavanagh; Asif J Iqbal; Sian Lax; Neena Kalia; Alex Brill; Steve G Thomas; Antonio Belli; Nicholas Crombie; Rachel A Adams; Shelley-Ann Evans; Hans Deckmyn; Janet M Lord; Paul Harrison; Steve P Watson; Gerard B Nash; G Ed Rainger Journal: Haematologica Date: 2019-08-29 Impact factor: 9.941